RU2445970C1 - Herbal agent for treating and preventing urinary stone disease - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to preparing herbal agents showing nephrolytic action, and is applicable for treating and preventing urinary stone disease. The herbal agent for treating and preventing urinary stone disease contains bearberry leaves, common madder roots and rhizomes, bottle brush herb, knotgrass herb, rose hip, peppermint leaves, Indian kidney tea leaves or birch leaves, horseheal roots and rhizomes and wild strawberry leaves in certain proportions.

EFFECT: herbal agent enables extending the spectrum of therapeutic action, improves tissue metabolic processes, controls homeostasis and provides higher non-specific body resistance; what is important for this agent is its prophylactic efficacy during remission, and also no side effects.

2 tbl

Description

The invention relates to medicine, namely to the creation of herbal medicines with nephrolytic effect, and can be used for the treatment and prevention of urolithiasis.

Urolithiasis occupies one of the leading places in the structure of urological diseases in terms of frequency of spread, hospitalized morbidity and the place among the most common surgical diseases in patients who go to the ambulance and come to the hospital urgently.

Urolithiasis, or urolithiasis, occurs in at least 1-3% of the population, and most often in people of working age - 20-50 years. Patients with urolithiasis account for 30-40% of the total contingent of urological hospitals.

Annually 85 thousand diseases of urolithiasis are registered, with 62 thousand of them recurrent stones.

In the occurrence and development of urolithiasis, an important role is played by metabolic disorders: phosphoric-calcium, uric and oxalic acids, rarely amino acids. Important factors in the formation of urinary stones are impaired hemo- and urodynamics of the upper urinary tract, decreased blood flow and ureter in the kidneys, infections, climate factor, as well as a high content of mineral salts in drinking water, etc.

Due to these reasons, calculus is deposited in the kidneys and in the upper urinary tract. In addition to the most common urate stones, stones are found whose main components are other salts: oxalates, phosphates, and combinations of these salts. Urate precipitates in an acidic environment; their formation contributes to an excess of purine bases in food. Phosphates are formed in an alkaline environment and are observed with excessive consumption of vegetables and fruits. Oxalates precipitate at a urine pH of ~ 5.5 and an increase in the concentration of calcium ions; the formation of calcium-oxalate stones contributes to the excess intake of oxalic acid or substances that form oxalates as a result of metabolism (for example, taking large doses of ascorbic acid).

Currently, several approaches are known in the treatment of urolithiasis. Among them are surgical, physio-, chemo- and therapeutic, as well as their combinations (complex therapy); sometimes homeopathic remedies and herbal remedies are used to treat and prevent urolithiasis.

Known drug "Urolesan" used to treat urolithiasis, containing fir oil, peppermint, castor oil and extracts of wild carrot seeds, hop cones and oregano grass with a certain content of components (MD Mashkovsky. Medicines. - A manual for doctors . - 15th ed., Revised., Revised and supplemented. - M.: “New Wave”, 2005, p. 519).

Known drug "Fitolizin" used for the treatment of urolithiasis, containing extracts of parsley root, wheatgrass rhizomes, horsetail grass, birch leaves, bird grass and other medicinal plants; and oils of mint, sage, pine, orange and vanillin. The drug has a diuretic, anti-inflammatory and antispasmodic effect; loosening of stones occurs slowly (ibid., p. 520).

Known complex drug "Marelin" used to treat urolithiasis, which contains dry extracts of madder dye, grass horsetail, goldenrod; monosubstituted magnesium phosphate, korglikon, kellin and salicylamide with a certain content of ingredients. The drug has an antispasmodic, diuretic and anti-inflammatory effect; promotes the discharge of urinary calculi, consisting of calcium oxalates and calcium phosphates (ibid., p. 518), but does not contribute to the discharge of urate calculi.

Known urological (diuretic) collection, used in the form of a decoction for urolithiasis, containing bearberry leaves, calendula flowers, dill, rhizomes and roots of Eleutherococcus and peppermint leaves with a certain ratio of components; the collection has a diuretic, anti-inflammatory, antispasmodic and antimicrobial effect (Radar of Russia, 9th issue, 2002, p. 873). The use of this collection does not always lead to a clinical effect, since it does not have a significant effect on diuresis and does not always normalize the function of the urinary system.

Known tool used in urolithiasis in the case of stones of oxalate-calcium nature, which is obtained by extraction of leaves of Eriobotrya japonica and subsequent purification. The agent is effective when used over an extended period of time (EP 0652761, 1995).

Known phytoconcentrate of therapeutic and prophylactic action used in diseases of the kidneys and bladder, including and in urolithiasis, including quercetin, or dihydroquercetin, or rutin, or ascorutin, bird of the mountaineer, leaves of birch, columns with stigmas of corn, grass of a three-part sequence, meat concentrate, or chicken, or vegetable with a certain content of components (patent RU 2122421, 1997). Phytoconcentrate does not give the desired clinical effect due to the lack of components that have antispasmodic and nephrolytic effects.

Known drug "Cyston" (India) containing Didomocarpus pedicellata, Jaxifraga Ligulata, Rubia cardifolia, Cyperus scariosus, Achyranthes aspera, Onosma bracteatum, Verninia cinerea, Shilajeet and Hayrul yahood bhasma with a certain content of components; the drug regulates the crystal-colloidal balance of urine and is used for the treatment and prevention of urolithiasis (Russian Radar 6th ed., 1999, p. 823).

The drug has a pronounced therapeutic effect when used for a long period of time 4-5 months and, in addition, contains hard-to-reach tropical raw materials.

Known drug for the treatment of urolithiasis according to patent No. 2281781, IPC: А61К 36/899, including fruits of common juniper, cones of common hop, lingonberry leaves, field horsetail grass, sweet clover grass, shepherd’s bag grass, blue cornflower grass, flax seeds, grass seeds parsley, madder roots, linden flowers, bird of the mountaineer, perforated St. John's wort grass, roots of the field gland, kidney tea grass, rhizomes and roots of angelica officinalis, the fruits of anise officinalis, birch buds, three violet grass vetnoy, fennel fruit, corn silk, Helichrysum arenarium flowers, roots and rhizome, licorice root, dandelion root medicament, bearberry ordinary grass, grass wormwood, taken in a certain ratio. When applying this collection, it is possible to increase choleresis, which subsequently leads to seizures of cholecystitis due to the content of anise fruits, corn stigmas, immortelle flowers and dandelion roots. Especially dangerous collection will be with calculous cholecystitis.

The closest in composition to the claimed invention is a phyto-remedy "NEFROLIT" according to patent No. 2211870, IPC: А61К 35/78, containing bearberry leaves, rhizomes and roots of madder rash, horsetail grass, bird grass, rosehips, peppermint leaves, kidney tea leaves or birch leaves in the following ratio of ingredients, including:

Bearberry leaves 1-6

Rhizomes and roots of madder 1-6

Horsetail Grass 1-6

Highlander's Grass 1-6

Rose hips 1-6

Peppermint Leaves 1-6

Kidney tea leaves or

Birch Leaves 1-6

The disadvantages of the analogues and the prototype are, first of all, the lack of a pronounced anti-inflammatory effect, the value of which for any drug used in the treatment of urolithiasis cannot be overestimated, since kidney stones cause not only inflammation of the mucous membrane of the pelvis and calyx, but also secondary interstitial nephritis. Infection and obstruction of the urinary tract exacerbate pathological changes (apostematous nephritis, calculous pyelonephritis, etc.) and impair the function of the kidney (lack of prototype).

In addition, the disadvantages of analogues and prototype include the lack in the spectrum of therapeutic action of the ability to increase nonspecific resistance of the body.

The objective of the invention is to expand the spectrum of therapeutic action of the drug due to the anti-inflammatory effect and the ability of the latter to improve metabolic processes in tissues, regulate homeostasis and increase nonspecific resistance of the body.

This task is achieved by the fact that phytochemicals for the treatment and prevention of urolithiasis, containing bearberry leaves, rhizomes and roots of madder, dyeing grass, horsetail grass, bird mountain grass, rosehips, peppermint leaves, kidney tea leaves or birch leaves, are introduced rhizomes and roots of elecampane high and wild strawberry leaves with the following contents of ingredients, in parts:

Bearberry leaves 1-6

Rhizomes and roots of madder 1-6

Horsetail Grass 1-6

Highlander's Grass 1-6

Rose hips 1-6

Peppermint Leaves 1-6

Kidney tea leaves or

Birch Leaves 1-6

Rhizomes and roots of elecampane high 1-6

Leaves of wild strawberry 1-6

In the clinic of the clinical hospital of the Moscow military district of the Ministry of Defense of Russia, clinical trials of the proposed phyto-drug were conducted.

The study involved 31 patients with urolithiasis after relief of an exacerbation (usually renal colic). Patients were on an outpatient basis. The experimental group consisted of 15 patients aged 28 to 45 years (mean age 33.7 ± 4.2 g). The control group included 16 patients comparable with the patients of the experimental group according to the nature of pathology and age (average age 36.4 ± 5.8 g). The diagnosis of urolithiasis in all patients was confirmed anamnestically, by clinical examination, as well as the results of laboratory and instrumental studies.

We studied the effectiveness of the herbal remedy "NEFROLIT" (prototype) and the proposed herbal remedy.

Ingredients Quantity (in parts) Prototype The proposed herbal remedy Rhizomes and roots of madder dyeing 1-6 1-6 Bearberry leaves 1-6 1-6 Grass horsetail 1-6 1-6 Highlander's Grass 1-6 1-6 Dog-rose fruit 1-6 1-6 Peppermint leaves 1-6 1-6 Kidney tea or birch leaves 1-6 1-6 Rhizomes and roots of elecampane high - 1-6 Leaves of wild strawberry - 1-6

Preparation of the product (infusion) was carried out as follows: about 10 g (2 tbsp. Tablespoons) of collection were placed in an enameled bowl, filled with water at room temperature 200 ml (1 cup) and heated in a boiling water bath for 15 minutes, cooled at room temperature for 45 minutes, filter. The remaining raw materials are squeezed out, the volume of the obtained infusion is adjusted to 200 ml with boiled water. Take for therapeutic purposes, 100 ml _^(1/2 cup) 3 times a day, prophylactically - 50 ml (1/4 cup) 3 times per day.

Patients in the test group of complex treatment infusion were used (proposed fitosredstv) _^1/2 cup 3 times a day. The course of treatment was 1 month. Patients in the control group used the phyto-drug NEFROLIT (prototype). At the end of the study (after 1 month), the patients of the experimental and control groups were recommended the prophylactic use of a new prescription.

The effectiveness of treatment was evaluated according to clinical signs by methods of comparing the results of treatment in the experimental and control groups. Patients evaluated the rate of relief of exacerbation, the number of attacks of renal colic, the elimination of dysuric phenomena and frequent urination. In the course of a laboratory study, the presence and severity of leukocyturia and bacteriuria were analyzed. Instrumental research methods included ultrasound examination of the kidneys, bladder.

The dynamics of clinical, laboratory and instrumental comparative indicators are shown in tables 1, 2.

The presented clinical and functional data indicate that the subjective assessment of the effectiveness of the treatment in patients of the experimental group was significantly better, namely: overall well-being, no pain attacks and dysuric disorders. In both groups, there were no side effects, as well as dyspeptic symptoms.

The data presented indicate that against the background of the used proposed in the invention funds in patients of the experimental group, the qualitative characteristics of the indicators exceed the indicators in the control group. During the ultrasound study before and after the course of treatment, a decrease in the size and number of renal calculi was reliably noted.

Moreover, in the experimental group, these indicators are better by 25%.

Of no small importance is the fact that at all stages of the clinical use of the drug collection, not a single patient had any undesirable drug reactions, including allergic reactions.

Comprehensive treatment with the inclusion of the test collection in patients of the experimental group within 5-6 days (an average of 5.1 ± 1.6 days) to achieve the abatement of the phenomena of exacerbation.

In patients of the control group, the rate of elimination of exacerbation was significantly lower (12-14 days, an average of 13.8 ± 2.0 days) and was less pronounced.

In general, the results of treatment of the experimental group could be characterized as follows: excellent - 10 patients (control group - 8), good - 4 (control group - 4), satisfactory - 1 person. (control group - 4).

Thus, the analysis of clinical, laboratory and instrumental studies allows us to conclude that the use of the proposed phytochemical in complex therapy of patients with urolithiasis is one of the promising directions in the treatment of this disease.

The inclusion of new components in it, namely: rhizomes and roots of elecampane high and leaves of wild strawberries accelerates the achievement of remission of the disease in the form of elimination of pain, reducing the number and frequency of renal colic; reduces treatment time due to the pronounced anti-inflammatory effect and increase nonspecific resistance of the body.

Important for this drug is its prophylactic effectiveness in the phase of remission of the disease, as well as the absence of side effects.

Table 1 The dynamics of clinical indicators during treatment Analyzed Clinical Data Patient groups Initial data Experienced group Control group Pain in the lumbar region (subjectively on a 5-point scale) 5 0-1 one Presence of attacks of renal colic ++ - + - Dysuric phenomena ++ - + - Dyspeptic disorders ++ - - Symptom of Pasternatsky ++ - + - Temperature rise 37.2 ± 0.6 36.6 ± 0.5 36.8 ± 0.8

table 2      The dynamics of laboratory parameters during treatment Analyzed Indicators Patient groups Initial data Experienced group Control group White blood cell count 11.6 ± 5.7 8.7 ± 4.3 9.4 ± 5.8 ESR 18.7 ± 4.8 6.0 ± 1.9 10.4 ± 2.8 The content of α ₂ -globin, PSA (degree of increase) +++ + ++ Bacteriuria (in 1 ml of urine) 135000 ± 3900 15000 ± 500 18000 ± 700 Leukocyturia 49000 ± 1600 5300 ± 800 8300 ± 300 The presence of salt crystals ++++ + + Urine specific gravity 1003.4 ± 25.6 1023.9 ± 123 1013.6 ± 15.8

Claims (1)

A phytochemical for the treatment and prevention of urolithiasis, containing bearberry leaves, rhizomes and roots of madder dye, grass horsetail, bird grass, rose hips, peppermint leaves, kidney tea leaves or birch leaves, characterized in that it is additionally included in its composition rhizomes and roots of elecampane high and leaves of wild strawberry in the following ratio of ingredients, in parts:
Bearberry leaves 1-6 Rhizomes and roots of madder dyeing 1-6 Grass horsetail 1-6 Highlander's Grass 1-6 Dog-rose fruit 1-6 Peppermint leaves 1-6 Kidney tea leaves or birch leaves 1-6 Rhizomes and roots of elecampane high 1-6 Leaves of wild strawberry 1-6